Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Ribosomal protein L21 pseudogene 65 (RPL21P65) is a processed pseudogene of the ribosomal protein L21 (RPL21) gene found in the human genome[3][6]. Pseudogenes are segments of DNA that resemble functional genes but typically do not encode active proteins and are not transcribed in a way that produces functional molecules. The functional RPL21 gene encodes a structural component of the 60S subunit of eukaryotic ribosomes and is essential for protein synthesis[1][2][7]. However, RPL21P65, as a pseudogene, is not translated into a functional protein and has no verified biological, therapeutic, or pharmacological significance. Its existence reflects the evolutionary history of the RPL21 gene family and processed pseudogenes commonly found in the genome.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on ribosomal protein L21 pseudogene 65 (RPL21P65).